These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27479870)

  • 1. Bioequivalence of Biosimilar Tumor Necrosis Factor-α Inhibitors Compared With Their Reference Biologics: A Systematic Review.
    Chingcuanco F; Segal JB; Kim SC; Alexander GC
    Ann Intern Med; 2016 Oct; 165(8):565-574. PubMed ID: 27479870
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of biosimilar insulins compared to their reference products: A systematic review.
    Tieu C; Lucas EJ; DePaola M; Rosman L; Alexander GC
    PLoS One; 2018; 13(4):e0195012. PubMed ID: 29668697
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Equivalence of Biosimilar and Reference Biologic Drugs in Rheumatoid Arthritis: A Systematic Review and Meta-analysis.
    Ascef BO; Almeida MO; Medeiros-Ribeiro AC; Oliveira de Andrade DC; Oliveira Junior HA; de Soárez PC
    JAMA Netw Open; 2023 May; 6(5):e2315872. PubMed ID: 37234004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and Effectiveness of Anti-Tumor Necrosis Factor-Alpha Biosimilar Agents in the Treatment of Psoriasis.
    Reynolds KA; Pithadia DJ; Lee EB; Liao W; Wu JJ
    Am J Clin Dermatol; 2020 Aug; 21(4):483-491. PubMed ID: 32048187
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Equivalence and switching between biosimilars and reference molecules in rheumatoid arthritis: protocol for a systematic review and meta-analysis.
    Ascef BO; Almeida MO; de Medeiros Ribeiro AC; Andrade DCO; de Oliveira Júnior HA; Pereira TV; de Soárez PC
    Syst Rev; 2021 Jul; 10(1):205. PubMed ID: 34274019
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of a proposed tocilizumab biosimilar MSB11456 versus both the US-licensed and EU-approved products: a randomized, double-blind trial.
    Schwabe C; Illes A; Ullmann M; Ghori V; Vincent E; Petit-Frere C; Monnet J; Racault AS; Wynne C
    Expert Rev Clin Immunol; 2022 May; 18(5):533-543. PubMed ID: 35354411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative functional and pharmacological characterization of Sandoz proposed biosimilar adalimumab (GP2017): rationale for extrapolation across indications.
    Kronthaler U; Fritsch C; Hainzl O; Seidl A; da Silva A
    Expert Opin Biol Ther; 2018 Aug; 18(8):921-930. PubMed ID: 29962245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review article on biosimilar infliximab SB2 in the treatment of rheumatoid arthritis.
    Bellinvia S; Ashraf M; Polosa R; Edwards C
    Immunotherapy; 2017 Nov; 9(14):1133-1142. PubMed ID: 29067885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Non-medical Switching from Originator Tumor Necrosis Factor Inhibitors to Their Biosimilars: Systematic Review of Randomized Controlled Trials and Real-World Studies.
    Numan S; Faccin F
    Adv Ther; 2018 Sep; 35(9):1295-1332. PubMed ID: 30084060
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AURIEL-PsO: a randomized, double-blind phase III equivalence trial to demonstrate the clinical similarity of the proposed biosimilar MSB11022 to reference adalimumab in patients with moderate-to-severe chronic plaque-type psoriasis.
    Hercogová J; Papp KA; Chyrok V; Ullmann M; Vlachos P; Edwards CJ
    Br J Dermatol; 2020 Feb; 182(2):316-326. PubMed ID: 31206593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An Update Review of Biosimilars of Adalimumab in Psoriasis - Bioequivalence and Interchangeability.
    Zhou X; Chen Z; Bi X
    Drug Des Devel Ther; 2021; 15():2987-2998. PubMed ID: 34267501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Switch from reference etanercept to SDZ ETN, an etanercept biosimilar, does not impact efficacy, safety, and immunogenicity of etanercept in patients with moderate-to-severe rheumatoid arthritis: 48-week results from the phase III, randomized, double-blind EQUIRA study.
    Jaworski J; Matucci-Cerinic M; Schulze-Koops H; Buch MH; Kucharz EJ; Allanore Y; Kavanaugh A; Young P; Babic G
    Arthritis Res Ther; 2019 May; 21(1):130. PubMed ID: 31138316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and metabolism of infliximab biosimilars - A new treatment option in inflammatory bowel diseases.
    Włodarczyk M; Fichna J; Sobolewska-Włodarczyk A
    Pharmacol Rep; 2016 Aug; 68(4):797-801. PubMed ID: 27162107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Etanercept biosimilar SB-4.
    Pelechas E; Drosos AA
    Expert Opin Biol Ther; 2019 Mar; 19(3):173-179. PubMed ID: 30616405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics of Clinical Trials Evaluating Biosimilars in the Treatment of Cancer: A Systematic Review and Meta-analysis.
    Bloomfield D; D'Andrea E; Nagar S; Kesselheim A
    JAMA Oncol; 2022 Apr; 8(4):537-545. PubMed ID: 35113135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-world observational study of biosimilars in inflammatory arthritis treatment: a systematic literature review.
    Kim JW; Jung JY; Suh CH
    Expert Opin Biol Ther; 2021 Jan; 21(1):57-73. PubMed ID: 32808557
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized controlled trial comparing PF-06438179/GP1111 (an infliximab biosimilar) and infliximab reference product for treatment of moderate to severe active rheumatoid arthritis despite methotrexate therapy.
    Cohen SB; Alten R; Kameda H; Hala T; Radominski SC; Rehman MI; Palaparthy R; Schumacher K; Schmitt S; Hua SY; Ianos C; Sewell KL
    Arthritis Res Ther; 2018 Jul; 20(1):155. PubMed ID: 30053896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Review of the Totality of Evidence Supporting the Development of the First Adalimumab Biosimilar ABP 501.
    Markus R; McBride HJ; Ramchandani M; Chow V; Liu J; Mytych D; Fanjiang G
    Adv Ther; 2019 Aug; 36(8):1833-1850. PubMed ID: 31183781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative Efficacy and Safety of Biosimilar Rituximab and Originator Rituximab in Rheumatoid Arthritis and Non-Hodgkin's Lymphoma: A Systematic Review and Meta-analysis.
    Lee S; Lee H; Kim E
    BioDrugs; 2019 Oct; 33(5):469-483. PubMed ID: 31446557
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.